CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma [0.03%]
CAR-T细胞疗法及双特异性抗体在多发性骨髓瘤治疗中的应用
Danai Dima,Rahul Banerjee,Doris K Hansen
Danai Dima
The introduction of CAR (chimeric antigen receptor) T-cell therapy and bispecific antibodies into clinical practice has revolutionized the treatment landscape of relapsed/refractory multiple myeloma (RRMM). Both modalities have shown impres...
Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight [0.03%]
非霍奇金淋巴瘤的新兴免疫治疗进展：在战斗中调动T细胞
Alexandra E Rojek,Sonali M Smith
Alexandra E Rojek
The treatment landscape of B-cell non-Hodgkin lymphoma (B-NHL) has been rapidly transformed by the emergence of T-cell engaging (TCE) therapies. Within the past decade, anti-CD19 chimeric antigen receptor (CAR) T-cell therapies have moved f...
Ruah Alyamany,Damon E Houghton
Ruah Alyamany
Hematologic malignancies are associated with an increased risk of venous thromboembolism (VTE) with aggressive lymphomas and multiple myeloma exhibiting the highest VTE incidence. The performance of VTE risk scores in hematologic malignanci...
Sigbjørn Berentsen
Sigbjørn Berentsen
Cold agglutinin disease (CAD) is an autoimmune hemolytic anemia, a specific clonal B-cell disorder of the bone marrow, and a monoclonal gammopathy of clinical significance. Thus, CAD should be distinguished from cold agglutinin syndrome, a ...
Salman Fazal,Yazan Samhouri,Cyrus Khan et al.
Salman Fazal et al.
Rare B-cell malignancies pose a unique management challenge because of their rarity and aggressiveness. Given their low incidence, they require a high index of suspicion for diagnosis and necessitate specialized therapeutic approaches. Here...
Peri-transplant conundrums: optimizing maintenance therapy using MRD-directed approaches [0.03%]
移植相关的困惑：使用微小残留病灶指导的方法优化维持治疗
Suravi Raychaudhuri,Ryan D Cassaday,Mary-Elizabeth M Percival
Suravi Raychaudhuri
Improved understanding of the molecular underpinnings of acute leukemia has led to advances in the detection of very low levels of leukemia-specific abnormalities, known as measurable residual disease (MRD). The limit of detection for moder...
Emerging genomic biomarkers in diagnosis and classification of T-cell acute lymphoblastic leukemia [0.03%]
T细胞急性淋巴细胞白血病诊断和分类的新兴基因生物标志物
Jason Xu,David T Teachey
Jason Xu
Contemporary chemotherapy protocols have improved cure rates for children, adolescents, and young adults (CAYA) with T-lineage acute lymphoblastic leukemia (T-ALL) to greater than 80%. Unfortunately, outcomes for CAYA with relapsed and refr...
New age GVHD prophylaxis regimens: what works for what donor and why [0.03%]
新型GVHD预防方案：什么样的方案适用于何种供者及其原因分析
Mahasweta Gooptu,John Koreth
Mahasweta Gooptu
Allogeneic hematopoietic stem-cell transplantation is a curative modality for hematologic malignancies, bone marrow failure syndromes, hemoglobinopathies, and other nonmalignant disorders. Graft-versus-host disease (GVHD)-in its acute or ch...
Kristen McClellan,Andrea Sitlinger
Kristen McClellan
The options for frontline chronic lymphocytic leukemia (CLL) treatment continue to expand. Therapies include monotherapy with a Bruton's tyrosine kinase inhibitor (BTKi), doublet therapies such as venetoclax with intravenous obinutuzmab or ...